Progress of small-molecule compounds combined with chimeric antigen receptor T-cell therapy for treatment of B lymphocyte malignancies

VernacularTitle:小分子药物联合嵌合抗原受体T细胞治疗B淋巴细胞恶性肿瘤的研究进展
Author: Jingwen RUI ¹ ; Biqi ZHOU ; Yang XU
Author Information

1. 苏州大学附属第一医院血液科　国家血液系统疾病临床医学研究中心　江苏省血液研究所　卫生部血栓与止血重点实验室　苏州大学造血干细胞移植研究所，苏州　215006
Keywords: B lymphocyte tumors; Chimeric antigen receptor T-cell; Drug therapy, combination; Cytokine release syndrome
From: Journal of Leukemia & Lymphoma 2024;33(11):692-695
CountryChina
Language:Chinese
Abstract: Chimeric antigen receptor T-cell (CAR-T) therapy has been widely used in patients with hematologic malignancies. However, there are still problems like high relapse rate and limited persistence. Challenges remain in enhancing the efficacy of CAR-T therapy while minimizing the adverse reactions. In recent years, small-molecule compounds, such as Bruton tyrosine kinase inhibitors, tyrosine kinase inhibitors and demethylating drugs, have been shown to have potential synergistic interactions when combined with CAR-T therapy. This review summarizes the latest progress of small-molecular compounds combined with CAR-T therapy in treatment of B lymphocyte malignancies.